期刊文献+

贝伐珠单抗联合化疗治疗复发及转移性子宫颈癌的安全性及近期疗效观察 被引量:7

原文传递
导出
摘要 子宫颈癌是全世界女性第3大常见肿瘤[1],复发、转移性子宫颈癌患者的治疗较为棘手,主要治疗方法为放疗和化疗,然而疗效往往不尽如人意。目前,对于贝伐珠单抗的研究日益增多,其对复发、转移性子宫颈癌患者也显示出良好的疗效[2]。郑州大学附属肿瘤医院妇科自2013年1月至2014年2月采用贝伐珠单抗联合化疗治疗15例复发、转移性子宫颈癌,现对其近期疗效及安全性进行回顾性分析。
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2015年第3期223-224,共2页 Chinese Journal of Obstetrics and Gynecology
  • 相关文献

参考文献15

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics[J].CA Cancer J Clin ,2011,61 (2):69-90.
  • 2Seol HJ,Ulak R,Ki KD,et al. Cytotoxic and targeted systemictherapy in advanced and recurrent cervical cancer: experiencefrom clinical trials[J]. Tohoku J Exp Med, 2014, 232 (4):269-276.
  • 3Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelinesto evaluate the response to treatment in solid tumors. EuropeanOrganization for Research and Treatment of Cancer, NationalCancer Institute of the United States,National Cancer Instituteof Canada[J]. J Natl Cancer Inst, 2000,92 (3 ) :205-216.
  • 4Monk BJ,Sill MW,McMeekin DS,et al. Phase M trial of fourcisplatin-containing doublet combinations in stage IV B,recurrent,or persistent cervical carcinoma: a GynecologicOncology Group study[J]. J Clin Oncol, 2009, 27 (28):4649-4655.
  • 5沈晓燕,崔恒.复发性和转移性子宫颈癌化疗的研究进展[J].中华妇产科杂志,2013,48(10):788-791. 被引量:11
  • 6Kerbel RS. Tumor angiogenesis[J]. N Engl J Med, 2008, 358(19):2039-2049.
  • 7Giantonio BJ,Catalano PJ,Meropol NJ,et al. Bevacizumab incombination with oxaliplatin,fluorouracil,and leucovorin(FOLFOX4)for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group StudyE3200[J]. J Clin Oncol,2007,25( 12):1539-1544.
  • 8Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial ofpemetrexed plus bevacizumab for second-line therapy ofpatients with advanced non-small-cell lung cancer: NCCTG andSWOG study N0426[J]. J Clin Oncol,2010,28(4):614-619.
  • 9Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumabcombined with chemotherapy for platinum-resistant recurrentovarian cancer: The AURELIA open-label randomized phase Mtrial[J]. J Clin Oncol,2014,32( 13):1302-1308.
  • 10Robert NJ, Dieras V,Glaspy J, et al. RIBBON-1: randomized,double-blind, placebo-controlled, phase HI trial ofchemotherapy with or without bevacizumab for first-linetreatment of human epidermal growth factor receptor 2-negative,locally recurrent or metastatic breast cancer[J]. J Clin Oncol,2011,29(10):1252-1260.

二级参考文献30

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin,2011,61:69-90.
  • 2Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin 0nco1,1985, 3:1079-1085.
  • 3Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of a rapid versus prolonged (24 hr ) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol, 1989,32 : 198-202.
  • 4McGuire WP 3rd, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix : a Gynecologic Oncology Group study. J Clin Onco1,1989,7:1462-1468.
  • 5McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oneology Group study. J Clin Oncol, 1996,14:792-795.
  • 6Curtin JP, Blessing JA, Webster KD, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol,2001,19:1275- 1278.
  • 7Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase ]I study of the Gynecologic Oncology Group. Gyneeol Onco1,2005,96 : 103-107.
  • 8Omura GA, Blessing JA, Vacearello L, et al. Randomized trial of cisplatin versos cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squaraous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol, 1997,15 : 165- 171.
  • 9Moore DH, Blessing JA, McQuellon RP, et al. Phase Ⅲ study of cisplatin with or without paclitaxel in stage IV B, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol,2004 ,22 :3113-3119.
  • 10Monk B J, Huang HQ, Cella D, et al. Quality of life outcomes from a randomized phase Ⅲ trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol,2005 ,23 :4617-4625.

共引文献10

同被引文献82

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部